Across TCGA pan-cancer cohorts, MIR548AX RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of MIR548AX’s most consistent transcriptional readouts.
The strongest signal is observed in breast invasive carcinoma (BRCA), where MIR548AX RNA is more highly expressed in tumor relative to normal tissue. In most cancer types MIR548AX is over-expressed in tumor, although a few such as LUSC show the opposite, repressed pattern.
BRCA and LUSC are the cancer types where MIR548AX tumor–normal differential expression is most reproducible.